

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number  
**WO 00/73801 A2**

- (51) International Patent Classification<sup>7</sup>: G01N 33/574, C12Q 1/68, A61K 39/00, 39/395, 35/14, 48/00, C12N 15/63, 5/10, C07K 14/47, 7/04, 16/18
- (72) Inventor; and  
(75) Inventor/Applicant (for US only): OBATA, Yuichi [JP/JP]; Chikusa-ku, Nagoya 464 (JP).
- (21) International Application Number: PCT/US00/14749
- (74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (22) International Filing Date: 26 May 2000 (26.05.2000)
- (81) Designated States (national): AU, CA, CN, JP, KR, US.
- (25) Filing Language: English
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (26) Publication Language: English
- (30) Priority Data:  
60/136,526 28 May 1999 (28.05.1999) US  
60/153,454 10 September 1999 (10.09.1999) US
- Published:  
— Without international search report and to be republished upon receipt of that report.
- (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/73801 A2

(54) Title: BREAST, GASTRIC AND PROSTATE CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

(57) Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

115 120 125  
 Leu Arg Gln Gln Gln Glu Leu Phe Ala Lys Ala Arg Gln Gln Gln Ala  
 130 135 140  
 Glu Leu Ala Gln Gln Glu Trp Leu Gln Met Gln Gln Ala Ala Gln Gln  
 5 145 150 155 160  
 Ala Gln Leu Ala Ala Ala Ser Ala Ser Ala Ser Asn Gln Ala Gly Ser  
 165 170 175  
 Ser Gln Asp Glu Glu Asp Asp Asp Asp Ile  
 180 185  
 10  
 <210> 606  
 <211> 328  
 <212> PRT  
 <213> Homo sapiens  
 15  
 <400> 606  
 Glu Pro Val Val Leu Arg Phe Met Ile Phe Cys Arg Leu Leu Ala Lys  
 1 5 10 15  
 Met Ala Asn Asn Asp Ala Val Leu Lys Arg Leu Glu Gln Lys Gly Ala  
 20 20 25 30  
 Glu Ala Asp Gln Ile Ile Glu Tyr Leu Lys Gln Gln Val Ser Leu Leu  
 35 40 45  
 Lys Glu Lys Ala Ile Leu Gln Ala Thr Leu Arg Glu Glu Lys Lys Leu  
 50 55 60  
 25 Arg Val Glu Asn Ala Lys Leu Lys Lys Glu Ile Glu Glu Leu Lys Gln  
 65 70 75 80  
 Glu Leu Ile Gln Ala Glu Ile Gln Asn Gly Val Lys Gln Ile Ala Phe  
 85 90 95  
 Pro Ser Gly Thr Pro Leu His Ala Asn Ser Met Val Ser Glu Asn Val  
 30 100 105 110  
 Ile Gln Ser Thr Ala Val Thr Thr Val Ser Ser Gly Thr Lys Glu Gln  
 115 120 125  
 Ile Lys Gly Gly Thr Gly Asp Glu Lys Lys Ala Lys Glu Lys Ile Glu  
 130 135 140  
 35 Lys Lys Gly Glu Lys Lys Glu Lys Lys Gln Gln Ser Ile Ala Gly Ser  
 145 150 155 160  
 Ala Asp Ser Lys Pro Ile Asp Val Ser Arg Leu Asp Leu Arg Ile Gly  
 165 170 175  
 Cys Ile Ile Thr Ala Arg Lys His Pro Asp Ala Asp Ser Leu Tyr Val  
 40 180 185 190  
 Glu Glu Val Asp Val Gly Glu Ile Ala Pro Arg Thr Val Val Ser Gly  
 195 200 205  
 Leu Val Asn His Val Pro Leu Glu Gln Met Gln Asn Arg Met Val Ile  
 210 215 220  
 45 Leu Leu Cys Asn Leu Lys Pro Ala Lys Met Arg Gly Val Leu Ser Gln  
 225 230 235 240  
 Ala Met Val Met Cys Ala Ser Ser Pro Glu Lys Ile Glu Ile Leu Ala  
 245 250 255  
 Pro Pro Asn Gly Ser Val Pro Gly Asp Arg Ile Thr Phe Asp Ala Phe  
 50 260 265 270  
 Pro Gly Glu Pro Asp Lys Glu Leu Asn Pro Lys Lys Lys Ile Trp Glu  
 275 280 285  
 Gln Ile Gln Pro Asp Leu His Thr Asn Asp Glu Cys Val Ala Thr Tyr  
 290 295 300  
 55 Lys Gly Val Pro Phe Glu Val Lys Gly Lys Gly Val Cys Arg Ala Gln  
 305 310 315 320  
 Thr Met Ser Asn Ser Gly Ile Lys  
 325  
 60  
 <210> 607  
 <211> 347  
 <212> PRT  
 <213> Homo sapiens